HOME >> BIOLOGY >> NEWS
Case Western Reserve University licenses methoxyamine to Tracon

CLEVELAND--Case Western Reserve University's Technology Transfer Office has entered a worldwide exclusive licensing agreement with TRACON Pharmaceuticals of San Diego, Calif., to develop Methoxyamine, a new cancer therapeutic that reverses cancer cell resistance to chemotherapy. Methoxyamine is a "first in class" drug that targets a specific DNA repair pathway.

TRACON Pharmaceuticals is an emerging biotechnology company focused on identifying, developing and commercializing targeted therapies for cancer and angiogenesis. TRACON's management team couples their ability to execute with their extensive knowledge of oncology drug development and first generation targeted therapies, enabling them to advance the development of next generation cancer therapies.

Methoxyamine was developed by University Hospitals Case Medical Center researchers Stanton Gerson, M.D., director of the National Cancer Institute-designated Case Comprehensive Cancer Center and University Hospitals Ireland Cancer Center, and Lili Lui, Ph.D., assistant professor of medicine in the department of hematology and oncology at the Case School of Medicine. They were the first to show the therapeutic potential of Methoxyamine as an anti-cancer drug in combination with other agents.

"We are very excited about the potential of this new drug. The promise of overcoming a major mechanism of drug resistance in cancer is terrific news for many patients. We see potential applications in patients with brain cancers, melanoma, lung cancer and leukemias and perhaps other cancers," said Gerson.

Under the licensing agreement, TRACON will develop and manage clinical trials of Methoxyamine. "We are excited to be able to develop Methoxyamine. Chemotherapy represents the most commonly used class of agents to treat cancer patients. Unfortunately, resistance of cancer cells to chemotherapy prevents many patients from benefiting. Methoxyamine's unique ability to reverse res
'"/>

Contact: Susan Griffith
susan.griffith@case.edu
216-368-1004
Case Western Reserve University
13-Oct-2006


Page: 1 2

Related biology news :

1. Study finds Western-style meat-sweet diet increases risk of breast cancer in postmenopausal women
2. Case Western Reserve University School of Medicine researchers awarded $27M for TB research
3. Case Western researcher, international team call for better global warming forecasting
4. WHSRN awarded major grant to foster shorebird conservation throughout the Western Hemisphere
5. Case Western Reserve University biologists suspect lightning fires help preserve oak forests
6. Case Western Reserve University chemist takes on HIV-1 virus with $1M support from NIH
7. Case Western Reserve University paleontologist discovers South American mammal fossils
8. Case Western Reserve University researchers find protein associated with brain cell death
9. In Western bluebird as well as human families, accumulated wealth encourages stability
10. Case Western Reserve University School of Medicine gets $4 million to make smart nanoparticles
11. ASU students host first annual Western Regional Bioethics Conference

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... ... June 25, 2020 , ... ... biopharmaceutical R&D, today announced that it has entered into a multi-year contract ... (Multiclonics®), to support their translational and clinical research strategy to discover and ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical ... clinical data services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: ... in hospitalized patients with severe COVID-19. This is the first study of an ...
(Date:6/23/2020)... ... June 23, 2020 , ... First Aid Africa, a ... UK supplier and manufacturer of innovative portable renewable energy equipment, have announced the ... against the COVID-19 pandemic in Zambia. , One of Renovagen’s FAST FOLD portable ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... Slone Partners , ... announced the placement of Julianne Averill , CPA, as Chief Financial Officer ... operations and implementing key business strategies to accelerate Alveo’s growth as the company ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... available for free its new white paper – Simulated Transport Methodologies. Regulatory ... today’s biologics licensing application (BLA). In response, Modality Solutions shares an explanation ...
(Date:7/31/2020)... ... 2020 , ... R3 Stem Cell International is now offering patients the opportunity ... cells total, patients may choose which extremities they would like treated. , Several studies ... Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab with ...
(Date:7/31/2020)... ... 29, 2020 , ... eSource has long been touted as the solution to ... of eSource, the reasons it did not take off as quickly as people initially ... industry is moving towards capturing data electronically for clinical trials and then repurposing it ...
Breaking Biology Technology:
Cached News: